Abstract:Invasive fungal infection (IFI) remains as a significant cause of morbidity and mortality in patients with acute myelogenous leukemia (AML). Here, we report the subgroup analysis of China Assessment of Antifungal Therapy in Haematological Disease (CAESAR) study to evaluate the risk of IFI in patients with AML in 1st remission receiving high-dose cytarabine (HiDAC) as consolidation. A total of 638 patients with AML in 1st complete remission were selected from the database. Among them, 130 patients received HiDAC alone with total dose of 2-3 g/m(2) × 6 while 508 patients received multiple-agent combination chemotherapy (multiagent chemo group). The patients' characteristics were generally not different but more patients in HiDAC group had peripherally inserted central catheter (61.5% vs 44.5%, P = 0.002). The median duration of neutropenia was 8.0 days in both HiDAC (2-20) and multiagent chemo group (2-28). Number of patients with prolonged neutropenia (>14 days) tended to be more in multiagent chemo group but not significant different (16.3% vs 8.8%, respectively). There was no significant difference between 2 groups in persistent neutropenic fever (40.8% vs 33.1%), antifungal treatment (11.5% vs 11.4%), and incidence of proven/probable IFI (4 probable in HiDAC vs 1 proven/4 probable in multiagent chemo, P = 0.35) or possible IFI. As to the clinical outcome in terms of duration of hospitalization and death in remission, there was a trend of shorter duration of hospitalization in HiDAC (19 days, 3-70) compare to multiagent chemo group (21 days, 1-367, P = 0.057) while no death documented in HiDAC group and only 2 patients died in the multiagent chemo group (0.4%). As to risk factors associated with IFI in all 638 patients, there was a trend of more IFI in patients with severe neutropenia (3.0%, P = 0.089) and previous history of IFI (3.85%, P = 0.086) while the antifungal prophylaxis was not associated significantly reduced IFI. Overall, our data support the perception that HiDAC alone as consolidation in first remission AML patients was well tolerated and not associated with increased hematological toxicity and IFI than conventional combination chemotherapy. Antifungal prophylaxis may not necessary except for patients with previous history of IFI.

Short-Course Rather Than Low-Dose Amphotericin B May Exert Potential Influence on Mortality in Cryptococcal Meningitis Patients Treated with Amphotericin B Plus Flucytosine Alone or in Combination with Fluconazole

Treatment of cryptococcal meningitis with low-dose amphotericin B and flucytosine.

Importance Of Fibrosis 4 Index Score And Mode Of Anti-Fungal Treatment To The Outcome Of Cryptococcal Meningitis In Hepatitis B Virus-Infected Patients

[Clinical Study of Amphotericin B in the Treatment of Invasive Fungal Infection in 111 Hematological Disorder Patients with Neutrocytopenia].

Unique Clinical Features of Cryptococcal Meningitis among Chinese Patients Without Predisposing Diseases Against Patients with Predisposing Diseases

[Evaluation of Low-Dose Amphotericin B and Flucytosine in the Treatment of Cryptococcal Meningitis].

Amphotericin B Plus Fluorocytosine Combined with Voriconazole for the Treatment of Non-Hiv and Non-Transplant-associated Cryptococcal Meningitis: a Retrospective Study

Voriconazole Plus Flucytosine is Not Superior to Amphotericin B Deoxycholate Plus Flucytosine As an Induction Regimen for Cryptococcal Meningitis Treatment.

Does High-Dose Cytarabine Cause More Fungal Infection in Patients with Acute Myeloid Leukemia Undergoing Consolidation Therapy

Observation on the treatment efficacy of Cryptococcal neoformans meningitis

Analysis of the Relationship Between Drug Susceptibility of Cryptococcus Neoformans Isolates and Mortality in HIV-negative Cryptococcal Meningitis

Clinical features and antifungal therapeutic effects of 154 patients with cryptococcal meningitis

Antifungal Therapy for Treatment of Cryptococcal Meningitis

HIV Infection Does Not Increase 10-Week Mortality of Chinese Cryptococcal Meningitis Patients

Safety of different amphotericin B formulations among AIDS patients with invasive fungal disease: a retrospective observational study

Clinical analysis of cryptococcal meningitis:21 cases

Patterns of Amphotericin B Use and Factors Related to Mortality in a Low-Middle Income Country: An Observational and Longitudinal Study

Comparison of Amphotericin B, Flucytosine, and Voriconazole with Amphotericin B and Flucytosine in the Treatment of Cryptococcal Meningitis in AIDS

Concentrations of amphotericin B in body fluid from patients with AIDS-associated cryptococcal meningitis

Impact of high MIC of fluconazole on outcomes of Candida glabrata bloodstream infection: a retrospective multicenter cohort study.

Infectious Diseases Physician Management of Cryptococcal Meningitis in North America – Is Single High-Dose Liposomal Amphotericin B Being Used?